Clinical trials
Hepatitis B clinical trials
Below are recruiting hepatitis b clinical trials, each written for real people, not researchers. We’re tracking 152 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06885710RecruitingPhase 1
T cell therapy with antivirals for chronic hepatitis B
This study tests a new treatment that uses your own immune cells (T cells) modified to attack the hepatitis B virus, combined with standard antiviral medication. It is for people with chronic hepatitis B who have a specific HLA type and no advanced liver scarring.
ShanghaiAges 18–65 - NCT07240350Recruiting
Hepatitis B immune response in surgery patients
This study looks at how the body's immune system responds in people with chronic hepatitis B who also need surgery on certain organs. The goal is to learn more about the immune reaction in tonsils, lymph nodes, or other tissues to help find better treatments for hepatitis B.
Guangzhou, GuangdongAges 18–75 - NCT07511218RecruitingPhase 1
Study of AHB-171 for stable chronic hepatitis B
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
Ch’ang-ch’un, JilinAges 18–65 - NCT07573943RecruitingPhase 4
ASC22 with peginterferon to cure chronic hepatitis B
This trial tests whether combining ASC22 with peginterferon can help people with chronic hepatitis B achieve a functional cure (clearing the virus for good). It's for patients whose HBsAg levels are very low and who are already on stable treatment.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07169656Recruiting
Study on reducing liver cancer risk in hepatitis B patients
This study looks at how well different hepatitis B treatments help lower the risk of liver cancer. It's for people with chronic hepatitis B who are already using or starting certain antiviral or interferon therapies.
AnyangAges 18 years+ - NCT07051187RecruitingPhase 1
WGc0201 for chronic hepatitis B
This trial tests a new drug called WGc0201 in adults with chronic hepatitis B who have controlled their virus with standard antiviral pills. It aims to see if WGc0201 can further reduce hepatitis B surface antigen (HBsAg) levels.
Chengdu, SichuanAges 18–65 - NCT07519330RecruitingPhase 2
Testing HH-006 treatment for chronic hepatitis B
This study tests a new drug called HH-006 to see if it can help treat chronic hepatitis B infection. Participants will be grouped by their infection level, and the study checks whether the drug is safe and works to reduce the hepatitis B virus.
Chongqing, Chongqing MunicipalityAges 18–45 - NCT07610772RecruitingPhase 1
Safety study of a new hepatitis B antibody for hepatitis D
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
AarhusAges 18–70 - NCT05181826Recruiting
Blood collection study for cancer and benign diseases
This study collects blood samples from people with different health conditions (cancer, diabetes, liver disease, etc.) and from healthy volunteers. The goal is to find markers in the blood that could help detect or monitor diseases.
Redondo Beach, CaliforniaAges 18 years+ - NCT06617000RecruitingPhase 1
Immune cell therapy for hepatitis B-related liver cancer
This study tests a new immune cell therapy (SCG101) for people with a certain type of liver cancer linked to hepatitis B. It's designed for those whose cancer has progressed after standard treatments.
Beijing, Beijing MunicipalityAges 18–70 - NCT06668727RecruitingPhase 1
Testing a new antibody for hepatitis B safety
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
Aarhus NAges 18–70 - NCT05417932RecruitingPhase 1/Phase 2
Cell therapy for hepatitis B–related liver cancer
This Phase 1/2 study tests a lab-made cell treatment (SCG101) for people with hepatitis B–related liver cancer who have already had standard treatments. It aims to shrink tumors and improve outcomes in carefully selected patients.
New York, New YorkAges 18–70 - NCT06650852RecruitingPhase 2
A study of 3 drugs for chronic hepatitis B
This trial tests a combination of three drugs (BRII-179, BRII-835, and PEG-IFNα) to see if they can better control chronic hepatitis B. It is for people who are already on antiviral therapy and have well-controlled virus levels.
Beijing, Beijing MunicipalityAges 18–60 - NCT06947499RecruitingPhase 2/Phase 3
Testing a 6-in-1 infant vaccine in healthy babies
This study tests a new vaccine that protects babies against 6 diseases (diphtheria, tetanus, whooping cough, hepatitis B, polio, and Hib) in just one shot. It’s for healthy infants starting at 6–8 weeks old as their first series of vaccinations.
Dasmariñas, CaviteAges 1 month–2 months - NCT07370207RecruitingPhase 2
Study of AHB-137 for HBeAg negative chronic hepatitis B
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
Fitzroy, VictoriaAges 18–65 - NCT05769816RecruitingPhase 2
Combination treatment aimed to cure chronic hepatitis B
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT06696664Recruiting
Genetic study of chronic hepatitis B cure with long-acting interferon
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
Beijing, Beijing MunicipalityAges 18–70 - NCT04690972Recruiting
Collection of blood and tissue samples for liver disease research
This study builds a research library of biological samples (like tissue and blood) from people with chronic liver disease. It aims to create better lab and preclinical models of tumors and long-term liver problems, which may help future treatments.
StrasbourgAges 18 years+ - NCT04310787Recruiting
Tracking outcomes in adults with hepatitis B liver failure
This study looks at long-term survival in people ages 18–65 who are hospitalized with hepatitis B–related acute-on-chronic liver failure. It may help doctors better predict prognosis and improve care for people with this serious condition.
Guangzhou, GuangdongAges 18–65 - NCT05988879Recruiting
Functional cure for hepatitis B in HIV/HBV co-infection
This trial tests whether people with both HIV and hepatitis B can achieve a functional cure for hepatitis B. It aims to see if current treatment can be stopped safely after the hepatitis B virus is no longer active.
Guangzhou, GuangdongAges 18–65 - NCT06779864Recruiting
Hepatitis B virus genetics and drug resistance study
This study looks at how hepatitis B virus changes in your body, including mutations and drug resistance, using your blood or liver tissue samples. Understanding these changes could help improve treatment for hepatitis B.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07417553RecruitingPhase 2
Hydronidone capsules for hepatitis B-related liver scarring
This study tests a new capsule called hydronidone for people with liver scarring caused by chronic hepatitis B. You must already be on stable hepatitis B treatment and have moderate to advanced scarring.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT00001971Recruiting
Evaluation of patients with liver disease
This research study evaluates people with liver disease or at risk for liver disease, and compares them with healthy volunteers. The goal is to better understand liver disease and improve how doctors diagnose and treat it.
Bethesda, MarylandAges 2–100 - NCT07146100Recruiting
Long-term follow-up after AHB-137 treatment for hepatitis B
This study follows participants with chronic hepatitis B who previously responded to the drug AHB-137. The goal is to track long-term health and safety after their treatment.
Chongqing, Chongqing MunicipalityAges 18 years+
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis b?
- Yes. Clin2 currently lists 152 recruiting hepatitis b studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis b trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis b trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.